Argus analyst David Toung raised the firm’s price target on Silk Road Medical to $32 from $24 and keeps a Buy rating on the shares. The company recently launched the NPS PLUS and the tapered carotid stent, and with several quarters of solid financial results, Silk Road Medical is continuing on its path to operating profitability, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SILK: